Algiax is a company founded in 2011 headquartered in Germany. Brouky records 1 investor associated with the company.
Algiax is a clinical-stage biotech company developing AP-325 to treat peripheral post-surgical neuropathic pain; its Phase 2 study reported meaningful pain reduction with fewer side effects. The company focuses on developing novel therapeutics for neuropathic pain.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.